As the curtain closed on 2024, we reflect on a remarkable year that pushed boundaries, forged new partnerships, and redefined possibilities in precision oncology. From breaking new ground in computational intelligence to making meaningful global connections, the company’s journey this year has been nothing short of transformative.
Let’s take a closer look at the highlights of this impactful year.
The year kicked off with a bang as our CEO, Istvan Petak, MD, PhD, took center stage at Silicon Valley's Precision Medicine World Conference (PMWC). Presenting advancements in computational intelligence for precision oncology, the event opened doors to high-level engagements with industry leaders and ignited exciting new collaborations.
Next, we’ve set up for significant progress on the Genomic Noise Cancelling (GNC) Project, part of the Eurostars program. This initiative focuses on improving the detection of actionable cancer variants from genomic data. Genomate plays a pivotal role in developing noise-canceling algorithms, providing biomarker scores to define critical variants, and contributing to clinical validation. With this project, we aim to enhance cancer diagnostics and empower oncologists with precise tools for personalized treatment, further solidifying our leadership in precision oncology.
To further our mission, we partnered with Intelligene Healthcare in India, marking a significant step toward expanding access to personalized cancer care in a rapidly growing market. This collaboration represents a pivotal move toward making precision oncology accessible to each patient. Oncologists will gain access to comprehensive genomic insights and personalized treatment recommendations, ultimately enhancing the quality of care for Indian cancer patients.
In February, we celebrated the contributions of women in science as part of Women in Science Day. By spotlighting the critical roles of female scientists in advancing precision oncology, we underscored our commitment to fostering diversity and equality—values that drive our innovation forward.
March was a milestone month for us as we graduated from the prestigious Mayo Clinic Platform_Accelerate program. Armed with invaluable resources and insights gained during this experience, we strengthened our ability to deliver groundbreaking cancer care solutions, solidifying our leadership in the field.
April brought a significant financial boost, with our team securing $2.25 million in funding to advance computational models for predicting targeted cancer therapy responses. This funding fueled our innovation and reinforced our investors' trust in our mission to revolutionize personalized oncology.
Additionally, we reached a critical milestone with the launch of Phase 3 of the INSTAND-NGS4P initiative, a collaborative effort with Euformatics and BC Platforms. This one-year project focuses on clinical testing of our joint solution for NGS reporting in precision oncology across three clinical sites in Europe. By validating this combined approach, we aim to deliver a more robust and efficient solution for precision oncology, further advancing our commitment to improving patient outcomes and empowering healthcare providers with cutting-edge tools.
At the American Society of Clinical Oncology (ASCO) 2024 conference, we showcased our cutting-edge research by publishing two abstracts highlighting the predictive power of the Genomate®(DDA) score in cancer therapies. Vodicska et al. presented evidence from publicly available clinical trial data demonstrating that the Genomate® (DDA) score is predictive of immune checkpoint therapy response in lung cancer, while Dirner et al. shared real-world clinical evidence showing that the Genomate®(DDA) score effectively predicts targeted therapy responses, including immune checkpoint inhibitors, in lung cancer.
📄 Vodicska et al. https://meetings.asco.org/abstracts-presentations/232329
📄 Dirner et al. https://meetings.asco.org/abstracts-presentations/237182
June was a month of significant milestones for Genomate Health. We officially joined the Personalized Medicine Coalition (PMC), aligning with our mission to advance personalized healthcare through innovative genetic solutions. This membership underscores our commitment to contributing to developing and implementing tailored treatments based on unique genetic profiles, pushing the boundaries of patient care. Additionally, we joined the NVIDIA Inception Program, which provided us with access to advanced computational tools, further enhancing our precision oncology solutions.
On June 22, our CEO, Istvan Petak, MD, PhD, delivered an insightful talk at the "Drug Development in Oncology 2024" conference, organized by the IOSI Oncology Institute of Southern Switzerland and Institut Curie in Bellinzona.
Lastly, we demonstrated our commitment to sustainability through a partnership with Evertreen.com, supporting reforestation efforts and highlighting the intersection of health and environmental stewardship.
In July, we continued our advocacy for patients with rare cancers, such as sarcoma and bone cancer, bringing attention to these often-overlooked conditions. By doing so, we reaffirmed our commitment to equitable cancer care and addressing the unmet needs of underserved communities.
We were also honored to be selected for the prestigious Plug and Play UK Health Accelerator Program as part of their second cohort, enabling us to collaborate with global experts to enhance patient outcomes.
On July 17, we hosted the "Matching Patients with Treatments" webinar, led by our CEO, Istvan Petak, MD, PhD, and organized by Cancer Patient Lab. This insightful online event delved into advanced strategies in precision oncology to improve treatment matching based on individual molecular profiles. Attendees gained expert insights into the intricate process of using technology to tailor treatments to each patient's unique profile, paving the way for the future of personalized medicine.
August unfolded as a testament to Genomate Health’s vision and the power of collaboration. It began featured in OncoDaily Dialogue #9 - István Peták on Precision Medicine: Challenges, Journey, and Future, hosted by Roupen Odabashian MD, FRCPC, ABIM, sharing our vision for how computational intelligence reshapes cancer care. This platform allowed us to connect with a wide audience, illustrating the real-world impact of precision oncology and the potential to revolutionize patient outcomes.
Across the globe, at the AI4VN 2024 conference in Hanoi, our trusted distributor, Digosys, introduced Genomate®and the Genous™ service. The event, a gathering of leading innovators in AI, provided the perfect backdrop to showcase how our precision oncology solutions are shaping the future of healthcare. Digosys captivated the audience, demonstrating how our technology tailors treatments to each patient’s genetic profile, delivering personalized care where it is needed most. Deputy Prime Minister Tran Luu Quang, who visited the Genous™ booth, expressed strong interest in the innovative cancer treatment solution, signaling the Vietnamese government’s support for healthcare advancements and technology-driven solutions in oncology.
Back home, we celebrated another impactful milestone by contributing to CancerX’s Digital Navigation ROI Calculator and Digitally Enabled Patient Navigation Blueprint. These resources empower patient navigators to improve access to care while reducing the financial burden on patients. Our collaboration with CancerX goes beyond innovation—it’s about directly enhancing the quality of life for families navigating the challenges of cancer. By leveraging digital solutions, we’re helping bridge the gap between technology and compassionate care.
September was a month of purpose and innovation at Genomate Health. During Childhood Cancer Awareness Month, we focused on championing initiatives to improve outcomes for young cancer patients. A key highlight was our active participation in the CancerX Summit, which underscored the power of collaboration and digital innovation in oncology. The summit’s priorities aimed to tackle unmet cancer research and care needs through transformative digital health solutions. Together with fellow participants, we contributed to generating actionable concepts for projects and accelerator activities that leverage these innovations. The event also facilitated meaningful opportunities for collaboration within the CancerX community and with federal representatives, aligning our mission with impactful initiatives that improve cancer care on a broad scale.
October marked a pivotal chapter in Genomate Health’s journey, showcasing our relentless pursuit of innovation and global impact. Our CEO, Istvan Petak, MD, PhD, took the stage at the prestigious Plug and Play UK Health EXPO, presenting our groundbreaking solutions to an international audience. This high-profile event underscored the transformative potential of our precision oncology technologies and fostered new opportunities for collaboration and investment.
The month also brought a historic achievement for Genomate Health: the granting of our first patent, SYSTEM AND METHOD FOR ADAPTIVE MEDICAL DECISION SUPPORT (European Patent Application No. 15 839 067.4). This milestone solidifies our position at the forefront of innovation in precision oncology. The patented technology represents a breakthrough in medical decision-making, enabling clinicians to integrate complex molecular data for more effective and personalized cancer treatment recommendations.
In Vietnam, we solidified our presence through a series of in-person events led by our Founder and CEO, Dr. Istvan Petak, MD, PhD. These events, hosted by prestigious medical institutions such as Hanoi Oncology Hospital and K Hospital, showcased our advanced cancer treatment solutions to Vietnam’s top oncologists and healthcare leaders. Dr. Petak's presentations explored breakthroughs in precision oncology, including AI-driven molecular profiling, targeted therapy, and immunotherapy optimization. These sessions not only facilitated knowledge exchange but also fostered collaborations with local experts, further establishing Genomate® as a key player in Vietnam’s oncology landscape.
On November 21, Dr. Istvan Petak delivered a keynote at the SAKK Winter Semi-Annual Meeting (Swiss Oncology and Hematology Congress 2024) in Basel. His talk, titled Implementation of Computer-Assisted Precision Oncology in Clinical Practice and Clinical Research, emphasized how advanced technologies are transforming cancer care and accelerating clinical research. This presentation further reinforced our role as innovators in the global oncology community.
We have also embarked on a collaborative paid pilot project with Philips, focusing on providing actionable insights into targeted therapies for prostate cancer. Leveraging retrospective data of a published cohort, the project aimed to analyze whole-exome sequencing (WES) data, with a focus on targeted therapy options and immune checkpoint inhibitors.
Adding to the month’s achievements, our Chief of Staff, Ioana Stupariu, took the stage at the Plug and Play Tech Center’s Silicon Valley Summit. Ioana’s presentation highlighted our ongoing innovations and strengthened our position among global leaders in health tech. This event also marked the completion of the Plug and Play Healthtech UK and Plug and Play SV Insurtech Accelerators.
December marked a significant milestone in our global impact: we received our first patient request from Vietnam. This moment symbolizes the tangible reach of our mission and the trust placed in Genomate Health to deliver personalized, effective cancer care to patients worldwide.
Adding to the excitement, Genomate Health was selected as a finalist in the Digital Health Rewired Pitchfest 2025. This recognition highlights our commitment to revolutionizing cancer care through precision oncology. With Genomate®, we are empowering clinicians to navigate the complexities of cancer diagnostics and treatment decisions with greater ease and precision. This nomination reflects our dedication to improving patient outcomes and supporting healthcare systems like the NHS.
In 2024, our global story came full circle. From sharing our expertise on international stages to supporting families through practical, patient-focused innovations, we demonstrated that Genomate Health is more than a company—it’s a commitment to transforming the future of cancer care through ingenuity and compassion.
As we step into 2025, our vision remains bold and unwavering. This year, we aim to expand our global footprint further, building on the momentum and exploring new opportunities in emerging markets. We will focus on advancing commercialization efforts, securing FDA approval for our breakthrough designation, securing the ISO 27001 and ISO 13485 certifications and introducing enhanced features that make Genomate® even more impactful for clinicians and patients. Stay tuned!
.png)
